ライフサイエンスコーパス: arrhythmogenic

1 rophin deficient), the SSC was excessive and arrhythmogenic.

2 educing its slope, rendering the tissue less arrhythmogenic.

3 bition or genetic deletion of NOX2 prevented arrhythmogenic abnormalities in vivo during high stature

4 ng-induced cardiomyopathy and attenuation of arrhythmogenic activity.

5 o 48 hours of exposure to the drug generated arrhythmogenic afterdepolarizations and >/=15-fold incre

6 al cardiac cells, in turn, is accompanied by arrhythmogenic afterdepolarizations thought to trigger t

7 omyocytes to spontaneous Ca(2+)-releases and arrhythmogenic afterdepolarizations, particularly upon e

8 ayed prolonged action potential duration and arrhythmogenic afterdepolarizations.

9 problem differently making the prediction of arrhythmogenic and/or antiarrhythmic effects difficult.

10 ent of chemokines, extracellular matrix, and arrhythmogenic arrays confirmed the dysregulation of mul

11 sease candidates potentially contributing to arrhythmogenic atrial substrate.

12 us node dysfunction in CPVT, and whether the arrhythmogenic beats originate from the conduction syste

13 Kcne3 deletion is therefore arrhythmogenic by a novel mechanism in which secondary h

14 cteristic properties of TCWs are potentially arrhythmogenic by promoting both conduction block and re

15 oportion of A103V-CaM is sufficient to evoke arrhythmogenic Ca disturbances via ryanodine receptor 2

16 roportion of CPVT-CaM is sufficient to evoke arrhythmogenic Ca disturbances, whereas LQTS-CaMs do not

17 ains an effective inhibitor of RyR2-mediated arrhythmogenic Ca release even when cardiac sodium chann

18 c reticulum (SR) Ca releases (Ca sparks) and arrhythmogenic Ca waves.

19 Here, we report a new role for NAADP in arrhythmogenic Ca(2+) release in cardiac myocytes evoked

20 itates spontaneous Ca(2+) release in form of arrhythmogenic Ca(2+) waves and spontaneous action poten

21 he myocyte level, PLN ablation converted the arrhythmogenic Ca(2+) waves evoked by high extracellular

22 ulum, and the frequency of Ca(2+) sparks and arrhythmogenic Ca(2+) waves remains low.

23 The higher propensity of arrhythmogenic Ca(2+) waves resulted from the combined a

24 lls were also more susceptible to developing arrhythmogenic Ca(2+) waves which might form the substra

25 waves and a larger fraction of waves (termed arrhythmogenic Ca(2+) waves) triggered APs and global Ca

26 Ca2+ sparks, arrhythmogenic Ca2+ waves, sarcoplasmic reticulum (SR) C

27 ilies with somatic mosaicism associated with arrhythmogenic calmodulinopathy, and demonstrate dysregu

28 a release channels in the heart, but whether arrhythmogenic CaM mutants alter RyR2 function is not kn

29 This is in stark contrast to the actions of arrhythmogenic CaM mutations N54I, D96V, N98S, and D130G

30 growth and viability, yet the effect of the arrhythmogenic CaM mutations on cell viability, as well

31 f RyR2 as well as the mechanistic effects of arrhythmogenic CaM mutations.

32 We found that all structures of the arrhythmogenic CaM-N53I variant are highly similar to th

33 Brugada syndrome (BrS) is a highly arrhythmogenic cardiac disorder, associated with an incr

34 milies, including hypertrophic, dilated, and arrhythmogenic cardiomyopathies and inherited arrhythmia

35 pping phenotype of dilated and left-dominant arrhythmogenic cardiomyopathies complicated by frequent

36 ause hypertrophic, dilated, restrictive, and arrhythmogenic cardiomyopathies.

37 and the development of high-risk dilated and arrhythmogenic cardiomyopathies.

38 Desmoglein 2 gene (DSG2) mutations cause arrhythmogenic cardiomyopathy (AC) in human and transgen

39 Arrhythmogenic cardiomyopathy (AC) is a hereditary cardi

40 Arrhythmogenic cardiomyopathy (AC) is a hereditary disea

41 Arrhythmogenic cardiomyopathy (AC) is an inherited heart

42 Arrhythmogenic cardiomyopathy (AC) is associated with mu

43 e mutation of which has been associated with arrhythmogenic cardiomyopathy (AC).

44 pot for pathogenic mutations associated with arrhythmogenic cardiomyopathy (AC).

45 major pathological features pathognomonic in arrhythmogenic cardiomyopathy (AC).

46 Arrhythmogenic cardiomyopathy (ACM) is a variably penetr

47 Arrhythmogenic cardiomyopathy (ACM) is an inherited arrh

48 Arrhythmogenic cardiomyopathy (ACM) is an inherited hear

49 Inflammation is a prominent feature of arrhythmogenic cardiomyopathy (ACM), but whether it cont

50 cardiomyocytes, are the predominant cause of arrhythmogenic cardiomyopathy and can be identified in a

51 r early cardiac arrhythmias in patients with arrhythmogenic cardiomyopathy and cardiocutaneous syndro

52 as sarcomeric, force generation disease; and arrhythmogenic cardiomyopathy as desmosome, cell junctio

53 Cardiomyocyte ILK deletion produces a lethal arrhythmogenic cardiomyopathy associated with important

54 rdium has revealed mechanistic insights into arrhythmogenic cardiomyopathy but cardiac samples are di

55 DSP cardiomyopathy is a distinct form of arrhythmogenic cardiomyopathy characterized by episodic

56 The diagnosis of arrhythmogenic cardiomyopathy does not rely on a single

57 ALVC) is an under-characterized phenotype of arrhythmogenic cardiomyopathy involving the LV ab initio

58 Arrhythmogenic cardiomyopathy is a genetic disorder char

59 Arrhythmogenic cardiomyopathy is an inherited heart musc

60 RATIONALE: Arrhythmogenic cardiomyopathy is caused primarily by mut

61 nderstanding of the pathogenic mechanisms of arrhythmogenic cardiomyopathy over the past decade have

62 Buccal mucosa cells from arrhythmogenic cardiomyopathy patients exhibit changes i

63 kedly diminished in buccal mucosa cells from arrhythmogenic cardiomyopathy patients with known desmos

64 re responsible for a subset of patients with arrhythmogenic cardiomyopathy who exhibit cardiac arrhyt

65 of titin's spring region is associated with arrhythmogenic cardiomyopathy, a disease characterized b

66 y of long-QT syndrome, Brugada syndrome, and arrhythmogenic cardiomyopathy, and in the study of funct

67 human PKP2 associate with a life-threatening arrhythmogenic cardiomyopathy, often of right ventricula

68 cause loss of junctional Pg is a hallmark of arrhythmogenic cardiomyopathy.

69 excess cardiac fibroadipocytes, as in human arrhythmogenic cardiomyopathy.

70 2 (PKP2), is the most common causal gene for arrhythmogenic cardiomyopathy.

71 and drug screens for effective therapies in arrhythmogenic cardiomyopathy.

72 ar mechanisms underlying the pathogenesis of arrhythmogenic cardiomyopathy.

73 S probable by FDG PET cases were found to be arrhythmogenic cardiomyopathy.

74 M20 cardiomyopathy as a highly penetrant and arrhythmogenic cardiomyopathy.

75 Arrhythmogenic cardiomyopathy/arrhythmogenic right ventr

76 The most aggressive arrhythmogenic cardiomyopathy/ARVC subtype is ARVC type

77 anish family with inherited left ventricular arrhythmogenic cardiomyopathy/dysplasia and a high incid

78 nts presented data consistent with inherited arrhythmogenic cardiomyopathy/dysplasia phenotype with v

79 auses predominant inherited left ventricular arrhythmogenic cardiomyopathy/dysplasia with a high inci

80 histochemistry was compatible with inherited arrhythmogenic cardiomyopathy/dysplasia, and the functio

81 ion as a cause of inherited left ventricular arrhythmogenic cardiomyopathy/dysplasia.

82 Arrhythmogenic cardiovascular disease is associated with

83 ven to be a useful model system to delineate arrhythmogenic cardiovascular disease mechanisms.

84 y is a viable strategy to reduce the risk of arrhythmogenic CaT alternans.

85 onarrhythmogenic can suppress the ability of arrhythmogenic cells to generate delayed and early after

86 y sustained high atrial activation rates and arrhythmogenic cellular Ca2+ signaling instability; howe

87 rhythmias in vitro by preventing potentially arrhythmogenic changes in action potential characteristi

88 Atrial fibrillation (AF) requires arrhythmogenic changes in atrial ion channels/receptors

89 In arrhythmogenic conditions, such as cardiac hypertrophy a

90 GF-beta1 signaling completely abolished both arrhythmogenic conditions.

91 KCNE1 association protects KCNQ1 from an arrhythmogenic (constitutive current-inducing) effect of

92 ycin, no instances of Torsade de pointes, or arrhythmogenic death were reported.

93 rome (ACS) and a marker of increased risk of arrhythmogenic death.

94 the medications due to QT prolongation, and arrhythmogenic death.

95 No arrhythmogenic deaths were reported.

96 Congenital Long QT syndrome (LQTS) is an arrhythmogenic disorder that causes syncope and sudden d

97 Brugada syndrome (BrS) is an arrhythmogenic disorder that has been linked to mutation

98 ersen-Tawil Syndrome type 1 (ATS1) is a rare arrhythmogenic disorder, caused by loss-of-function muta

99 ern of NaV1.5 subunits associated with these arrhythmogenic disorders and the associated channel regu

100 and may contribute to CaMKIIdeltac-dependent arrhythmogenic disorders in failing hearts.

101 ations in several ion currents contribute to arrhythmogenic drug activity.

102 y associated with QT prolongation and may be arrhythmogenic during AVB.

103 cal problem worldwide, but it is unclear how arrhythmogenic early afterdepolarizations (EADs) are tri

104 explore the potential antiarrhythmic and/or arrhythmogenic effect of modulation of the autonomic ner

105 n or pharmacological inhibition prevents the arrhythmogenic effects of a high saturated fat diet, in

106 iological models of hMSCs, predicts possible arrhythmogenic effects of hMSCs when directly coupled to

107 Arrhythmogenic effects were studied using caffeine.

108 lore the potential role of Wnt signalling in arrhythmogenic electrical remodelling, we examined volta

109 aps before and after ajmaline determined the arrhythmogenic electrophysiological substrate (AES) as c

110 ociated cardiovascular death but not serious arrhythmogenic endpoints like sudden cardiac arrest (SCA

111 current can delay or even entirely suppress arrhythmogenic events.

112 system development and the observation that arrhythmogenic foci can originate in areas near the atri

113 tissue correspond to a region enriched with arrhythmogenic foci, which may reflect a common developm

114 mosomes and intermediate filaments, cause an arrhythmogenic form of cardiomyopathy that has been vari

115 evidence that deceleration zones are highly arrhythmogenic, functioning as niduses for reentry.

116 tivity to isoproterenol-induced induction of arrhythmogenic I(Na,L), and reduced CaMKII-dependent pho

117 Some but not all drugs designated as arrhythmogenic IKr blockers can generate arrhythmias by

118 cium affinity to the myofilament may promote arrhythmogenic intracellular calcium waves, we modified

119 anied by activation of large and potentially arrhythmogenic inward INCX.

120 diac hypertrophy and Epac2 activation can be arrhythmogenic, it is unknown whether distinct subcellul

121 did not bind to the main binding site of the arrhythmogenic KV11.1 blockers (the Phe656 pore residue)

122 Arrhythmogenic left ventricular cardiomyopathy (ALVC) is

123 radigm to screen drugs for QT prolonging and arrhythmogenic liability.

124 perties thought to predict QT prolonging and arrhythmogenic liability.

125 ions such as carbon-12 ((12)C), delivered to arrhythmogenic locations of the heart could be a promisi

126 We propose a previously unrecognized arrhythmogenic mechanism related to PKP2 expression and

127 olarization and may protect hearts from this arrhythmogenic mechanism.

128 otential (AP) duration (APD) is a well-known arrhythmogenic mechanism.

129 d of familial and genetic screening, and the arrhythmogenic mechanisms in the largest cohort of short

130 extracardiac pathogenesis when investigating arrhythmogenic mechanisms, even in inherited, monogenic

131 ent-(+)-verticilide prevented arrhythmogenic membrane depolarizations in cardiomyocyte

132 ls have proven challenging to use, targeting arrhythmogenic metabolic changes and redox imbalance may

133 rategy can be designed to correct a specific arrhythmogenic mutation, as in the catecholaminergic pol

134 Most of the identified arrhythmogenic mutations reside in the C-terminal domain

135 mechanisms by which autonomic activation is arrhythmogenic or antiarrhythmic are complex and differe

136 different types of cardiac disease, such as arrhythmogenic or hypertrophic cardiomyopathy.

137 probands previously diagnosed with dilated, arrhythmogenic, or restrictive cardiomyopathies.

138 Pro-arrhythmogenic pacing protocols were applied to initiate

139 omain with RyR2 and thereby likely cause the arrhythmogenic phenotype of this mutation.

140 (+)-selective transport in hERG1, leading to arrhythmogenic phenotypes associated with long-QT syndro

141 nical dyskinesis has been implicated in many arrhythmogenic phenotypes.

142 us diastolic Ca(2+) release (DCR) can induce arrhythmogenic plasma membrane depolarizations, although

143 Arrhythmogenic PMs (N=35) exhibited higher number of PMC

144 ular myocyte to interrogate this potentially arrhythmogenic positive feedback in both control conditi

145 rt, for the induction of tachycardia and the arrhythmogenic potency of this drug.

146 However, the observed increase in arrhythmogenic potential is not due to a steepening of t

147 The arrhythmogenic potential of APD prolongation was also te

148 aneous action potentials, thus enhancing the arrhythmogenic potential of atrial cells.

149 1-active hMSCs supports the claim of reduced arrhythmogenic potential of this cell type with low hMSC

150 ients with heart failure, causes potentially arrhythmogenic reductions in slow delayed-rectifier K(+)

151 ram fractionation may be helpful to identify arrhythmogenic regions in the postinfarction heart.

152 ustained VT can distinguish exercise-induced arrhythmogenic remodeling from ARVC and post-inflammator

153 rn may allow distinguishing exercise-induced arrhythmogenic remodeling from ARVC and post-inflammator

154 Novel cardiomyopathies have been discovered (arrhythmogenic, restrictive, and noncompacted) and added

155 Data characterizing structural changes of arrhythmogenic right ventricular (RV) cardiomyopathy are

156 elates of left ventricular (LV) substrate in arrhythmogenic right ventricular (RV) cardiomyopathy are

157 etic resonance (MR) imaging in patients with arrhythmogenic right ventricular (RV) dysplasia/cardiomy

158 pholamban R14del mutation causes dilated and arrhythmogenic right ventricular cardiomyopathies and is

159 viduals), dilated cardiomyopathy (1/250) and arrhythmogenic right ventricular cardiomyopathy (1/5,000

160 ic polymorphic ventricular tachycardia (4%), arrhythmogenic right ventricular cardiomyopathy (4%), an

161 rtrophy (LVH) and/or fibrosis (n = 59, 16%); arrhythmogenic right ventricular cardiomyopathy (ARVC) (

162 ventricular tachycardia (CPVT) (n = 9 [8%]), arrhythmogenic right ventricular cardiomyopathy (ARVC) (

163 Although overlap with arrhythmogenic right ventricular cardiomyopathy (ARVC) h

164 Although the Task Force Criteria for arrhythmogenic right ventricular cardiomyopathy (ARVC) h

165 Arrhythmogenic right ventricular cardiomyopathy (ARVC) i

166 Arrhythmogenic right ventricular cardiomyopathy (ARVC) i

167 Arrhythmogenic right ventricular cardiomyopathy (ARVC) i

168 Arrhythmogenic right ventricular cardiomyopathy (ARVC) i

169 Arrhythmogenic right ventricular cardiomyopathy (ARVC) i

170 Arrhythmogenic right ventricular cardiomyopathy (ARVC) i

171 Arrhythmogenic right ventricular cardiomyopathy (ARVC) i

172 Arrhythmogenic right ventricular cardiomyopathy (ARVC) i

173 Arrhythmogenic right ventricular cardiomyopathy (ARVC) i

174 Arrhythmogenic right ventricular cardiomyopathy (ARVC) i

175 Arrhythmogenic cardiomyopathy/arrhythmogenic right ventricular cardiomyopathy (ARVC) i

176 Arrhythmogenic right ventricular cardiomyopathy (ARVC) i

177 d others such as strain imaging, to identify arrhythmogenic right ventricular cardiomyopathy (ARVC) i

178 Exercise has been proposed as a trigger for arrhythmogenic right ventricular cardiomyopathy (ARVC) p

179 Arrhythmogenic right ventricular cardiomyopathy (ARVC),

180 possibility of cardiomyopathy, specifically arrhythmogenic right ventricular cardiomyopathy (ARVC).

181 malities precede overt structural disease in arrhythmogenic right ventricular cardiomyopathy (ARVC).

182 k Force Criteria (rTFC) for the diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC).

183 on (TWI), may create diagnostic overlap with arrhythmogenic right ventricular cardiomyopathy (ARVC).

184 Myocarditis has been reported in arrhythmogenic right ventricular cardiomyopathy (ARVC).

185 ssess tissue and functional abnormalities in arrhythmogenic right ventricular cardiomyopathy (ARVC).

186 Our aim was to screen 315 patients with arrhythmogenic right ventricular cardiomyopathy (n = 111

187 onischemic dilated cardiomyopathy [NICM], 15 arrhythmogenic right ventricular cardiomyopathy [ARVC])

188 onance plus genetic variants associated with arrhythmogenic right ventricular cardiomyopathy and of a

189 rdioverter defibrillator (ICD) in males with arrhythmogenic right ventricular cardiomyopathy caused b

190 e 2010 International Task Force Criteria for arrhythmogenic right ventricular cardiomyopathy diagnosi

191 rline 2010 International Task Force Criteria arrhythmogenic right ventricular cardiomyopathy diagnosi

192 Arrhythmogenic right ventricular cardiomyopathy diagnost

193 Thus, the hypothesis of an exercise-induced arrhythmogenic right ventricular cardiomyopathy has to b

194 ablation of ventricular tachycardia (VT) in arrhythmogenic right ventricular cardiomyopathy improves

195 In diagnosed channelopathy or arrhythmogenic right ventricular cardiomyopathy index ca

196 and adjuvant EPI substrate ablation of VT in arrhythmogenic right ventricular cardiomyopathy is good.

197 xed cardiomyopathies occur infrequently; and arrhythmogenic right ventricular cardiomyopathy is rare.

198 nd the desmosomal variants that cause either arrhythmogenic right ventricular cardiomyopathy or dilat

199 We identified arrhythmogenic right ventricular cardiomyopathy probands

200 Of 501 arrhythmogenic right ventricular cardiomyopathy probands

201 cutive patients with Task Force criteria for arrhythmogenic right ventricular cardiomyopathy referred

202 enes (PKP2, DSP, DSG2, DSC2, and JUP) from 3 arrhythmogenic right ventricular cardiomyopathy registri

203 was higher in nonischemic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy than in

204 for a possible primary electric syndrome or arrhythmogenic right ventricular cardiomyopathy were ana

205 pathy, 15 nonischemic cardiomyopathy, and 14 arrhythmogenic right ventricular cardiomyopathy) with a

206 ar tachycardia, 3; short QT syndrome, 1; and arrhythmogenic right ventricular cardiomyopathy, 23).

207 Long-QT, arrhythmogenic right ventricular cardiomyopathy, and cat

208 se each (3%) of hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, long QT

209 In patients with arrhythmogenic right ventricular cardiomyopathy, those d

210 that a mutation in alphaT-catenin linked to arrhythmogenic right ventricular cardiomyopathy, V94D, p

211 EPI) substrate modification in patients with arrhythmogenic right ventricular cardiomyopathy.

212 pathy that has been variably associated with arrhythmogenic right ventricular cardiomyopathy.

213 risk of developing dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy.

214 d to hypertrophic cardiomyopathy and none to arrhythmogenic right ventricular cardiomyopathy.

215 dress the current challenges associated with arrhythmogenic right ventricular cardiomyopathy/dilated

216 Heart failure (HF) prevalence in arrhythmogenic right ventricular cardiomyopathy/dysplasi

217 cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy/dysplasi

218 ers for risk stratification in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasi

219 ns were described in patients with inherited arrhythmogenic right ventricular cardiomyopathy/dysplasi

220 sisted of dilated cardiomyopathy (DCM, 49%), arrhythmogenic right ventricular dysplasia (ARVD, 17%),

221 netically uncharacterized diseases including arrhythmogenic right ventricular dysplasia 3.

222 earch has described the arrhythmic course of arrhythmogenic right ventricular dysplasia/cardiomyopath

223 Arrhythmogenic right ventricular dysplasia/cardiomyopath

224 M and they were diagnostic or suggestive for arrhythmogenic right ventricular dysplasia/cardiomyopath

225 ow overlap in the clinical presentation with arrhythmogenic right ventricular dysplasia/cardiomyopath

226 lete penetrance and variable expressivity of arrhythmogenic right ventricular dysplasia/cardiomyopath

227 can in turn facilitate ablation of the VT in arrhythmogenic right ventricular dysplasia/cardiomyopath

228 yopathy, left ventricular noncompaction, and arrhythmogenic right ventricular dysplasia; and delineat

229 spersion of repolarization, which could pose arrhythmogenic risk in LQTS patients.

230 The arrhythmogenic risk of such direct electrical interactio

231 too much IKs under basal conditions poses an arrhythmogenic risk.

232 issing and would assist in the evaluation of arrhythmogenic risk.

233 e heart's contractile activity and increased arrhythmogenic risks.

234 Thirty-two patients with arrhythmogenic RV cardiomyopathy (47+/-14 years; 6 women

235 cardiac magnetic resonance (CMR) imaging in arrhythmogenic RV cardiomyopathy (ARVC) may be inadequat

236 Further investigation did not diagnose arrhythmogenic RV cardiomyopathy in any athlete.

237 As, the potential for erroneous diagnosis of arrhythmogenic RV cardiomyopathy is considerably greater

238 In patients with arrhythmogenic RV cardiomyopathy presenting with recurre

239 ation is frequently present in patients with arrhythmogenic RV cardiomyopathy who have progressive RV

240 ck ventricular tachycardia in the setting of arrhythmogenic RV cardiomyopathy with procedures separat

241 LV substrate is frequent in arrhythmogenic RV cardiomyopathy, but poorly identified

242 commonly exhibit ECG anomalies that resemble arrhythmogenic RV cardiomyopathy.

243 c2 is located at the T tubules and regulates arrhythmogenic sarcoplasmic reticulum Ca leak.

244 We targeted arrhythmogenic scar regions by combining anatomical imag

245 Arrhythmogenic scar regions were targeted by combining n

246 r own appear as essential components of this arrhythmogenic scheme.

247 mmonly used clinical procedure that destroys arrhythmogenic sources in patients suffering from atrial

248 the propensity and reduced the threshold for arrhythmogenic spontaneous Ca(2+) release in HEK293 cell

249 CPVT myocytes also evidenced characteristic arrhythmogenic spontaneous Ca(2+) waves under cholinergi

250 Ca(2+) transient amplitude, but at a higher arrhythmogenic SR Ca(2+) leak.

251 PLN ablation aborts the arrhythmogenic SR Ca(2+) waves of S2814D(+/+) and transf

252 nucleoporins regulate pluripotency in a pro-arrhythmogenic stem cell line.

253 T isthmus may increase sensitivity to detect arrhythmogenic substrate and critical sites for reentry.

254 front may increase the sensitivity to detect arrhythmogenic substrate and critical sites for ventricu

255 l fibrillation are important elements of the arrhythmogenic substrate and result from endo-epicardial

256 d its possible value in the detection of the arrhythmogenic substrate associated with atrial fibrilla

257 LCS may provide an arrhythmogenic substrate by slowing the Ca(2+) transient

258 to identify the RVOT as the location of the arrhythmogenic substrate by the noninvasive CineECG, bas

259 of cardiac activation before ablation of the arrhythmogenic substrate can reduce electrophysiological

260 rial conduction abnormalities, presenting an arrhythmogenic substrate for atrial re-entry.

261 tions provide a well-established ventricular arrhythmogenic substrate for SCD.

262 ardiomyopathy (ARVC) has been suggested, the arrhythmogenic substrate for VTs in athletes is unknown.

263 adin, and/or junctin and RyR2 may produce an arrhythmogenic substrate in anthracycline-induced cardio

264 al fibrosis is an important component of the arrhythmogenic substrate in patients with atrial fibrill

265 e enabled characterization of the structural arrhythmogenic substrate in patients with VT with increa

266 ardial wall thinning (WT) imaged by MDCT and arrhythmogenic substrate in postinfarction ventricular t

267 Its arrhythmogenic substrate in the intact human heart remai

268 cardiac arrhythmia, but our knowledge of the arrhythmogenic substrate is incomplete.

269 hrone forces in the RVOT, congruent with the arrhythmogenic substrate location detected by epicardial

270 Inability to eliminate intramural arrhythmogenic substrate may lead to recurrent ventricul

271 assess whether prophylactic ablation of the arrhythmogenic substrate reduces or prevents the recurre

272 The posterior left atrium is an arrhythmogenic substrate that contributes to the initiat

273 ial function is thought to contribute to the arrhythmogenic substrate, but how mitochondria contribut

274 potential of CMR for characterization of the arrhythmogenic substrate, there is currently no standard

275 rial electrophysiology and predisposes to an arrhythmogenic substrate.

276 in, consistent with anatomic location of the arrhythmogenic substrate.

277 F, indicating that reduced Pitx2 promotes an arrhythmogenic substrate.

278 ing early formation and stabilization of the arrhythmogenic substrate.

279 ay support noninvasive identification of the arrhythmogenic substrate.

280 There are limited data on typical arrhythmogenic substrates and associated ventricular tac

281 Most studies of arrhythmia mechanisms and arrhythmogenic substrates have been conducted in animal

282 suggesting that VT and VF share overlapping arrhythmogenic substrates in patients with structural he

283 l redox state during cardiac diseases foment arrhythmogenic substrates through direct or indirect mod

284 age heart failure, beta2-stimulation creates arrhythmogenic substrates via conduction velocity regula

285 tent to which PI3K inhibition contributes to arrhythmogenic susceptibility.

286 ation, sustained ventricular tachycardia, or arrhythmogenic syncope.

287 ndrome (SQTS) is a rare and life-threatening arrhythmogenic syndrome characterized by abbreviated rep

288 The short QT syndrome (SQTS) is an inherited arrhythmogenic syndrome characterized by abnormal ion ch

289 An arrhythmogenic syndrome was the predominant diagnosis in

290 new genes associated with monogenic familial arrhythmogenic syndromes, giving the opportunity to deli

291 have been associated with various inherited arrhythmogenic syndromes, including Brugada syndrome and

292 have been associated with various inherited arrhythmogenic syndromes, including cases of Brugada syn

293 on targeting structural disorders or primary arrhythmogenic syndromes, respectively.

294 beta2-Stimulation is, therefore, more arrhythmogenic than beta1-stimulation.

295 patially discordant alternans, which is more arrhythmogenic than concordant alternans, may occur in t

296 exposed hearts showed increased incidence of arrhythmogenic-triggered activities in female ventricula

297 r atrial fibrillation (AF) aims to eliminate arrhythmogenic triggers from the PVs.

298 potentials in single cells which can lead to arrhythmogenic triggers in tissue.

299 nalling silencing) and Ca(2+) destabilizing (arrhythmogenic unstable Ca(2+) signalling) factors.

300 Ca(2+)-sensing protein calmodulin (CaM) are arrhythmogenic, yet their underlying mechanisms are not